Immunic, Inc., operating as Immunic Therapeutics, is a clinical-stage biopharmaceutical company developing selective, orally administered therapies for chronic inflammatory, autoimmune and neurologic diseases. Its research focuses on small-molecule drug candidates designed to address unmet medical needs, with an emphasis on treatment options that combine efficacy with safety and tolerability. Immunic’s clinical pipeline includes vidofludimus calcium, IMU-856 and IMU-381.

The company highlights vidofludimus calcium in its work targeting multiple sclerosis, seeking to advance oral treatment options for people with the disease. Its IMU-856 program is associated with the goal of developing convenient oral therapies for celiac disease, while IMU-381 is also listed among its pipeline programs. Immunic’s activities include drug discovery and development, clinical research, and sharing scientific and corporate updates through publications, presentations and news releases.

The company also provides investor information, including financial reports, stock data and corporate governance materials. With offices in New York and Gräfelfing, Germany, Immunic works to translate its scientific programs into potential medicines for patients living with serious chronic conditions